Skip to content
Buy This GLP
← Research
Evidence

Do People Fill Their GLP-1 Prescriptions? What Pharmacy Records Show

In one U.S. health system, about seven in ten patients with a new GLP-1 prescription had a documented fill within 30 days.

Editorial profile: Neil SandersBuy This GLP Editorial Team5 min read
New GLP-1 prescriptions at one health system70.2% documented fill29.8% no documented fill within 30 days

How many people filled a new GLP-1 prescription?

In one integrated U.S. health system, 726 of 2,435 patients (29.8%) with a new GLP-1 prescription from 2012 through 2019 had no documented pharmacy fill for a drug in that class within 30 days. That means 70.2% had a documented fill. The records could miss a fill paid in cash outside the health plan [1].

A Colorado study linked records for 9,848 orders and 6,094 patients enrolled in Medicare or commercial insurance between 2018 and 2022. Within 90 days, 60.1% of the orders had a recorded fill. That study counted initial orders and refill orders, and the rate varied by indication: 37.2% for obesity alone, 47.5% for diabetes alone and 64.6% for both [2]. Those figures describe the cohort. The GLP-1 insurance coverage guide explains how coverage rules can vary by diagnosis and plan.

What happens after an insurance denial?

The steps in GLP-1 prior authorization can affect when a pharmacy can bill a plan. In separate national claims data from 2018 through 2024, 34.1% of 173,782 people with a first observed denied claim and enough follow-up had a paid GLP-1 fill within 90 days. The data did not identify whether each denial reflected prior authorization, a formulary exclusion, step therapy or another reason [3].

In the 2022 Medical Expenditure Panel Survey, adults with type 2 diabetes and above-median income had higher odds of semaglutide use (OR 1.61, 95% CI 1.14 to 2.26). Private insurance was also associated with higher odds (OR 1.52, 95% CI 1.04 to 2.22). The survey measured use, so it cannot tell us the share of written prescriptions people filled [5].

What a two-drug trial adds

The PRECIDENTD feasibility report followed 173 adults with type 2 diabetes and cardiovascular disease or elevated cardiovascular risk. Nearly all had insurance. Participants were randomized to a GLP-1 receptor agonist, an SGLT2 inhibitor, or both. Within four months, 84% of those assigned either single drug reported obtaining it, compared with 53% assigned both who reported obtaining both. During median follow-up of ten months, those figures reached 87% and 68% [4].

Among those who obtained all assigned study medicines, 22% in the pooled single-drug group and 49% in the two-drug group stopped at least one, most often because of side effects. The study pooled two different single-drug groups and included participants already taking a GLP-1 at enrollment. It did not estimate a general first-fill rate for GLP-1 medicines or report the main trial’s long-term cardiovascular and kidney outcomes [4].

What happens after the first fill?

Studies measuring how long people stay on a GLP-1 start counting after the first fill. In one Kaiser Permanente Colorado cohort, 436 of 1,374 adults (31.7%) who first filled semaglutide or liraglutide between 2018 and 2023 stopped within 180 days. Among those who stopped, an adverse drug reaction was documented for 26.8% and a cost concern for 14.4%. The adjusted odds of stopping were higher for those with overweight or obesity alone than for those with both diabetes and overweight or obesity (OR 2.46, 95% CI 1.17 to 5.17) [6].

If cost affects whether you fill or refill, the guide to monthly GLP-1 costs explains which charges to confirm with the pharmacy or plan before comparing the first fill with later refills.

Frequently asked

How many people fill a new GLP-1 prescription?
In one U.S. health system, 70.2% of 2,435 patients newly prescribed a GLP-1 had a documented fill for a drug in the same class within 30 days. That study used 2012–2019 records and could miss cash fills outside the health plan.
Does an insurance denial mean a prescription will never be filled?
In a national claims study, 34.1% of people with a first observed denied GLP-1 claim and enough follow-up eventually had a paid GLP-1 fill within 90 days. The data cannot tell whether the first claim was reversed or a different GLP-1 was filled.
How many people stopped after filling?
In one Kaiser Permanente Colorado cohort, 31.7% of 1,374 adults who filled semaglutide or liraglutide stopped within 180 days. Adverse drug reactions and concerns about cost were among the documented reasons.

Sources

  1. [1] Luo J, et al. (2022). Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System Journal of General Internal Medicine. PMID 35048301
  2. [2] Sarpatwari A, Soto MJ, Ganguli I, Sloan CE, Goss F, Sinaiko AD (2025). Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and Indication JAMA Health Forum. Source
  3. [3] Jia M, et al. (2026). Prescription denials for GLP-1 receptor agonists across commercial, Medicare, and Medicaid coverage, 2018-2024 Health Affairs Scholar. PMID 42948647
  4. [4] Wexler DJ, et al. (2026). Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial American Heart Journal. PMID 41456635
  5. [5] Vaidya V, et al. (2026). Income disparities and accessibility to Semaglutide: implications for diabetes management and policy reform International Journal for Quality in Health Care. PMID 41437637
  6. [6] Van Laren J, et al. (2026). Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist Diabetes, Obesity and Metabolism. PMID 41713959

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence